BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37160694)

  • 21. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanism of gypenoside XVII against cerebral ischemia/reperfusion injury based on nuclear factor erythroid 2-related factor 2/antioxidant responsive element signaling pathway].
    Wang W; Xu Y; Xu S; Mao L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Mar; 35(3):293-298. PubMed ID: 36916343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The expression of Nrf2 and Keap1 in laryngeal carcinoma and its clinical indication].
    Yuan Y; Shan C; Xu O; Wang J; Zhang H
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jul; 29(13):1148-51. PubMed ID: 26540911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
    Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
    BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity.
    Li Y; Cui JT
    Biochem Biophys Res Commun; 2016 Sep; 477(4):607-613. PubMed ID: 27343560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
    Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
    Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different Inhibition of Nrf2 by Two Keap1 Isoforms α and β to Shape Malignant Behaviour of Human Hepatocellular Carcinoma.
    Chen F; Xiao M; Feng J; Wufur R; Liu K; Hu S; Zhang Y
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional Role of NRF2 in Cervical Carcinogenesis.
    Ma JQ; Tuersun H; Jiao SJ; Zheng JH; Xiao JB; Hasim A
    PLoS One; 2015; 10(8):e0133876. PubMed ID: 26247201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ARID1A loss is associated with increased NRF2 signaling in human head and neck squamous cell carcinomas.
    Nguyen V; Schrank TP; Major MB; Weissman BE
    PLoS One; 2024; 19(2):e0297741. PubMed ID: 38358974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
    Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
    Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
    Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
    Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
    Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
    Liu CJ; Chang WJ; Chen CY; Sun FJ; Cheng HW; Chen TY; Lin SC; Li WC
    Oncotarget; 2015 Oct; 6(30):29268-84. PubMed ID: 26337468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
    Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.